Senator Mario Scavello introduced Senate Bill 797 on May 28th that would require all students to receive a
meningococcal booster in the 7th and 12th grades. This bill has been referred to the Education Committee.
Did you know?
·
At any given time, up to 20 to 40% of the
population is asymptomatically colonizing meningococcal organisms in our nasal
passages and throats, which boosts our innate immunity to invasive bacterial
infection.[2]
[3]
·
By the time American children enter adolescence,
the vast majority have asymptomatically developed immunity that protects them.
·
The CDC
recommended meningococcal vaccine contains only one type, bacterial.
·
The
vaccine does not contain strain B, which is the strain associated with more
than 50% of the meningococcal cases and deaths.[7]
·
The
vaccine has been found to be, at best, only about 58% effective in adolescents
within 2-5 years after receiving it.[9] [10]
·
Symptoms of meningococcal disease include:
fever; severe headache; painful, stiff neck; nausea and vomiting; inability to
look at bright lights; mental confusion and irritability; extreme fatigue/sleepiness;
convulsions and unconsciousness.
·
The Meningococcal vaccine is currently available
to anyone who would like to use it.
There are several concerns with this bill as it seeks to
mandate another vaccine requirement for our school-aged children. This mandate would violate informed medical
consent and parental rights to decide what is best for our children’s care and
overall well-being.
Given the information stated above, this bill is not
necessary for the overall health of our adolescents. Please contact the members of the Senate
Education Committee to share your concerns regarding this bill.
[1]
www.cdc.gov/meningococcal/downloads/interim-guidance.pdfEndFragment
[2] Tan L KK, Cadone GM, Borrow R. Advances in the
development of vaccines against Neisseria meningitidis. NEJM April 22,
2010; 362(16): 1511-1520.
[3] Manchanda V. Gupta S., Bhalla P. Meningococcal
Disease: History, Epidemiology, Pathogenesis, Clinical Manifestations,
Diagnosis, Antiomicrobial Susceptibility and Prevention. Indian Journal of
Medical Microbiology 2006; 24(1): 7-19
[4] CDC. Meningitis Questions & Answers.
[5] http://www.musa.org/faq
[6] CDC.Meningococcal Disease and College Students. MMWR
June 30, 2000; 48(RR07): 11-20.
[7] Granoff DM. Review of Meningococcal Group B Vaccines.
Clinical Infectious Diseases
[8] http://www.ncbi.nlm.nih.gov/pubmed/21206392
[9] CDC. Updated Recommendations for Use of Meningococcal
Conjugate Vaccines – ACIP, 2010. JAMA 2011; 305(13): 1291-1293.
[10] Cohn A. Epidemiology of Meningococcal Disease in the
U.S. Presentation to the FDA Vaccines & Related Biological Products
Advisory Committee (VRBPAC). Transcript of April 6, 2011 Meeting. Pg 55-59.
[11]http://www.portal.state.pa.us/portal/server.pt/community/immunizations/14141/school_children_immunizations/557995
No comments:
Post a Comment